WO2011161232A1 - PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID - Google Patents

PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID Download PDF

Info

Publication number
WO2011161232A1
WO2011161232A1 PCT/EP2011/060606 EP2011060606W WO2011161232A1 WO 2011161232 A1 WO2011161232 A1 WO 2011161232A1 EP 2011060606 W EP2011060606 W EP 2011060606W WO 2011161232 A1 WO2011161232 A1 WO 2011161232A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
methyl
ethyl
compound
sulphamoyl
Prior art date
Application number
PCT/EP2011/060606
Other languages
French (fr)
Inventor
Tom Cornelis Hortense Govaerts
Jean-Pierre André Marc BONGARTZ
Patrick Hubert J. Nieste
Original Assignee
Tibotec Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112012032889A priority Critical patent/BR112012032889A2/en
Priority to US13/805,607 priority patent/US9127010B2/en
Priority to CN201180030949.0A priority patent/CN103097356B/en
Priority to CA2801517A priority patent/CA2801517C/en
Priority to RU2013103004/04A priority patent/RU2559886C2/en
Priority to EP11727184.1A priority patent/EP2585438B1/en
Application filed by Tibotec Pharmaceuticals filed Critical Tibotec Pharmaceuticals
Priority to MX2012015198A priority patent/MX2012015198A/en
Priority to JP2013515907A priority patent/JP5870098B2/en
Priority to AU2011268922A priority patent/AU2011268922B2/en
Publication of WO2011161232A1 publication Critical patent/WO2011161232A1/en
Priority to IL223427A priority patent/IL223427A/en
Priority to US14/810,783 priority patent/US20150329482A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/06—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to an improved method for the preparation of
  • WO 2010 / 003658 describes some macrocyclic indoles that can be used as inhibitors of the hepatitis C virus.
  • the aim of the present invention is to provide an improved method for the synthesis of 13-cyclohexyl-3-methoxy-6-[methyl-(2- ⁇ 2-[methyl-(sulphamoyl)-amino]-ethoxy ⁇ - ethyl)-carbamoyl]-7H-indolo-[2,l-(3]-[2]-benzazepine-10-carboxylic acid (Compound ' A') that is easier to carry out and is more efficient than the method known so far.
  • the present invention achieves this aim by providing an improved method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2- (2-[methyl-(sulphamoyl)- amino] -ethoxy ⁇ -ethyl)-carbamoyl]-7H-indolo-[2, l-a]-[2]-benzazepine-l 0-carboxylic acid ('Compound A'), characterized in that it comprises the following steps:
  • the coupling agent in Step a) is e.g. carbodiimidazole (CDI), dicyclohexylcarbodiimide (DCC), 0-(7-azabenztriazolo- 1 -yl)- 1,1,3 ,3-tetramethyluronium hexafluorophosphate (HATU), bromotri-(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP), a combination of 1-hydroxybenztriazole hydrate (HOBt.H 2 0) and l-ethyl-3-(3- dimethylaminopropyl)-carbodiimide hydrochloride (EDCI).
  • CDI carbodiimidazole
  • DCC dicyclohexylcarbodiimide
  • HATU 0-(7-azabenztriazolo- 1 -yl)- 1,1,3 ,3-tetramethyluronium hexafluorophosphate
  • a suitable solvent in Step a) is e.g. dichloromethane, 2-methyltetrahydrofuran, acetonitrile, acetone, 2-butanone, 4-methyl-2-pentanone, ethyl acetate, isopropyl acetate or toluene.
  • Step b) The hydrolysis in Step b) can be carried out by using trifluoroacetic acid,
  • methanesulphonic acid hydrogen chloride, hydrogen bromide, /?ara-toluenesulphonic acid, sulphuric acid or phosphoric acid.
  • Steps a) and b) can be carried out as a two-step synthesis, in which Compound (II) is isolated in Step a) before carrying out Step b), or else Steps a) and b) are conducted as a one- vessel synthesis.
  • the overall yield obtained in Steps a) and b) is between 86 and 91%, depending on which of the procedures described in Examples 3, 4 and 5 (Experiment B) is used to carry out the new method.
  • the present invention also relates to a new compound (Compound 'B') with the following formula, and possible acid-addition salts thereof:
  • the acid-addition salts of Compound 'B' include the salts that Compound 'B' can form with organic or inorganic acids, such as mineral acids, sulphonic acids, carboxylic acids and phosphorus-containing acids.
  • organic or inorganic acids such as mineral acids, sulphonic acids, carboxylic acids and phosphorus-containing acids.
  • salt-forming mineral acids are hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, sulphuric acid, nitric acid, chloric acid, perchloric acid and phosphoric acid.
  • Salt-forming sulphonic acids are toluenesulphonic acid, benzenesulphonic acid, methanesulphonic acid and trifluormethanesulphonic acid.
  • Salt-forming carboxylic acids are formic acid, acetic acid, propionic acid, butanoic acid and the like.
  • Salt-forming dicarboxylic acids are oxalic acid, malonic acid, succinic acid, glutaric acid and the like.
  • Salt-forming hydroxy-acids are glycollic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid and the like.
  • Other salt-forming carboxylic acids are trifluoroacetic acid, benzoic acid, chloroacetic acid, phthalic acid, maleic acid and malonic acid.
  • Phosphorus-containing acids are various phosphono-acids, phosphonic acids and phosphinic acids.
  • Step 1
  • CDI carbony ldiimidazo le
  • DIPE diisopropyl ether
  • MEK methyl ethyl ketone (2-butanone)
  • MIK methyl isopropyl ketone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)

Abstract

The present invention relates to an improved method for the preparation of 3-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}- ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid. The present invention also relates to a new compound, namely tert-butyl (methyl-{2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate, used in this improved method.

Description

PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2- [METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H- INDOLO-[2, 1 -a]-[2]-BENZAZEPINE- 10-CARBOXYLIC ACID
The present invention relates to an improved method for the preparation of
13-cyclohexyl-3-methoxy-6-[methyl-(2- {2-[methyl-(sulphamoyl)-amino]-ethoxy} - ethyl)-carbamoyl]-7H-indolo-[2,l-a]-[2]-benzazepine-10-carboxylic acid. The present invention also relates to a new compound, namely tert-butyl (methyl- {2- [2- (methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate, used in this improved method.
13-Cyclohexyl-3-methoxy-6-[methyl-(2- {2-methyl-(sulphamoyl)- amino]-ethoxy} -ethyl)-carbamoyl]-7H-indolo-[2, 1 -a]-[2]- benzazepine-10-carboxylic acid
Compound 'A'
fert-Butyl (methyl- {2-[2-(methylamino)-ethoxy]-ethyl} - sulphamoyl)-carbamate
Figure imgf000002_0001
Compound 'B'
WO 2010 / 003658 describes some macrocyclic indoles that can be used as inhibitors of the hepatitis C virus. The synthesis of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2- [methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,l- ]-[2]- benzazepine-10-carboxylic acid (Compound Ά') was described there on pages 38 and 39 (see Compound le) as a three-step synthesis, giving an overall yield of 62%.
Figure imgf000002_0002
Figure imgf000003_0001
Figure imgf000003_0002
The aim of the present invention is to provide an improved method for the synthesis of 13-cyclohexyl-3-methoxy-6-[methyl-(2- {2-[methyl-(sulphamoyl)-amino]-ethoxy } - ethyl)-carbamoyl]-7H-indolo-[2,l-(3]-[2]-benzazepine-10-carboxylic acid (Compound ' A') that is easier to carry out and is more efficient than the method known so far.
The present invention achieves this aim by providing an improved method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2- (2-[methyl-(sulphamoyl)- amino] -ethoxy} -ethyl)-carbamoyl]-7H-indolo-[2, l-a]-[2]-benzazepine-l 0-carboxylic acid ('Compound A'), characterized in that it comprises the following steps:
a) 10-(tert-butoxycarbonyl)- 13-cyclohexyl-3-methoxy- 7H-indolo-[2, 1 -a]-[2]- benzazepine-6-carboxylic acid (Compound I) is reacted with tert-butyl (methyl- {2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate (Compound 'B') in the presence of a coupling agent in a suitable solvent
Figure imgf000003_0003
(D 'B'
Figure imgf000004_0001
and Compound (II) thus obtained is hydrolysed with an acid to prepare Compound Ά'.
Figure imgf000004_0002
The coupling agent in Step a) is e.g. carbodiimidazole (CDI), dicyclohexylcarbodiimide (DCC), 0-(7-azabenztriazolo- 1 -yl)- 1,1,3 ,3-tetramethyluronium hexafluorophosphate (HATU), bromotri-(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP), a combination of 1-hydroxybenztriazole hydrate (HOBt.H20) and l-ethyl-3-(3- dimethylaminopropyl)-carbodiimide hydrochloride (EDCI).
A suitable solvent in Step a) is e.g. dichloromethane, 2-methyltetrahydrofuran, acetonitrile, acetone, 2-butanone, 4-methyl-2-pentanone, ethyl acetate, isopropyl acetate or toluene.
The hydrolysis in Step b) can be carried out by using trifluoroacetic acid,
methanesulphonic acid, hydrogen chloride, hydrogen bromide, /?ara-toluenesulphonic acid, sulphuric acid or phosphoric acid.
Steps a) and b) can be carried out as a two-step synthesis, in which Compound (II) is isolated in Step a) before carrying out Step b), or else Steps a) and b) are conducted as a one- vessel synthesis.
The overall yield obtained in Steps a) and b) is between 86 and 91%, depending on which of the procedures described in Examples 3, 4 and 5 (Experiment B) is used to carry out the new method. The present invention also relates to a new compound (Compound 'B') with the following formula, and possible acid-addition salts thereof:
Figure imgf000005_0001
fe^Butyl-(methyl-{2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate (Compound 'B')
The acid-addition salts of Compound 'B' include the salts that Compound 'B' can form with organic or inorganic acids, such as mineral acids, sulphonic acids, carboxylic acids and phosphorus-containing acids. Examples of salt-forming mineral acids are hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, sulphuric acid, nitric acid, chloric acid, perchloric acid and phosphoric acid. Salt-forming sulphonic acids are toluenesulphonic acid, benzenesulphonic acid, methanesulphonic acid and trifluormethanesulphonic acid. Salt-forming carboxylic acids are formic acid, acetic acid, propionic acid, butanoic acid and the like. Salt-forming dicarboxylic acids are oxalic acid, malonic acid, succinic acid, glutaric acid and the like. Salt-forming hydroxy-acids are glycollic acid, lactic acid, malic acid, tartaric acid, citric acid, mandelic acid and the like. Other salt-forming carboxylic acids are trifluoroacetic acid, benzoic acid, chloroacetic acid, phthalic acid, maleic acid and malonic acid.
Phosphorus-containing acids are various phosphono-acids, phosphonic acids and phosphinic acids.
This new Compound 'B' can be synthesized as follows:
Step 1 :
Figure imgf000005_0002
Figure imgf000006_0001
Figure imgf000006_0002
Experimental
The following abbreviations are used here:
A/A: active yield
CDI: carbony ldiimidazo le
CSI: chlorosulphonyl isocyanate
DBU: l,8-diaza-bicyclo-[5,4,0]-undecene-7
DIPE: diisopropyl ether
DMAP: 4-dimethylaminopyridine
DME: 1 ,2-dimethoxyethane
DMSO-d6: deuterated dimethylsulphoxide
EDCI: 1 -ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride
F/F: physical yield
HOBt: 1-hydroxybenzotriazole hydrate
iPrOAc: isopropyl acetate
LC: liquid chromatography
MeCN: acetonitrile
MEK: methyl ethyl ketone (2-butanone)
MeTHF: 2-methyltetrahydrofuran
MeS03H: methanesulphonic acid
MIK: methyl isopropyl ketone
MTBE: methyl tert-butyl ether
NMR: nuclear magnetic resonance
tBuOH: tert-butanol
tBOC: tert-butoxycarbonyl
THF: tetrahydrofuran Example 1
Intermediate (1)
Figure imgf000007_0001
A solution of 8.205 g of chlorosulphonyl isocyanate (58.0 mmol, 1 Eq) in 50 ml of acetonitrile (1 litre/mo 1) was cooled to -2°C on an ice/salt bath under nitrogen, using a 500-ml four-neck flask fitted with a thermometer, a magnetic stirrer and a dropping (addition) funnel. A solution of 4.297 g of tert-butanol (58.0 mmol, 1 Eq) in 33 ml of acetonitrile (0.5 1/mol) was added dropwise over 20 minutes, with the temperature remaining below 4°C. Four minutes later (when the temperature had dropped to 1°C), a solution of DMAP (116.0 mmol, 2 Eq) in 55 ml of acetonitrile (1 litre/mol) was added dropwise over 24 minutes, with the temperature remaining below 5°C.
The solution was allowed to stand for 65 minutes to ensure the best crystallization, with the temperature remaining below 3°C. The white suspension was filtered on a Buchner funnel filter, giving a non-tacky white powder. The precipitate was dried overnight in a drying cabinet at 40°C under vacuum, which gave 9.465 g of Intermediate (I).
Example 2
Compound 'B'
Figure imgf000007_0002
109.1 g (0.825 mol) of l,5-bis-(methylamino)-3-oxapentane and 1.5 litres of acetonitrile were introduced into a reaction vessel with an inert atmosphere. The resulting solution was cooled to 0°C, and 226 g (0.75 mol) of Intermediate (1) was added to it. The mixture thus obtained was stirred first for 6 hours at 10°C, and then for 3 days at 0°C. The precipitate was filtered off and washed with acetonitrile. After drying at 25°C, Compound 'B' was obtained in a yield of 95 g (40.6%, corrected for purity) in the form of white crystals. Example 3
Intermediate (2)
0.400 g (0.82 mmol, 1 Eq) of 10-(tert-butoxycarbonyl)-13-cyclohexyl-3-methoxy-7H- indolo-[2,l-a]-[2]-benzazepine-6-carboxylic acid (called Compound lb on page 38 of WO 2010 / 003658), 0.164 g of HOBt (1.07 mmol, 1.3 Eq) and 0.201g of EDCI (1.07 mmol, 1.3 Eq) were dissolved in 6.5 ml of MeTHF (8 1/mol) in a closed glass flask. The contents of the flask were stirred for 1 hour at room temperature. 0.469 g of Compound 'B' (64.3 wt-%, 0.98 mmol, 1.2 Eq) was then added to the reaction mixture, which was analysed after a reaction time of 18 hours. Analysis by LC indicated that
Intermediate (2) had been obtained in a yield of 93.1 %.
Example 4
Intennediate (2)
12.00 g (24.61 mmol, 1 Eq) of 10-(tert-butoxycarbonyl)-13-cyclohexyl-3-methoxy-7H- indolo-[2,l-a]-[2]-benzazepine-6-carboxylic acid, 4.92 g of HOBt (31.99 mmol, 1.3 Eq) and 6.03 g of EDCI (31.99 mmol, 1.3 Eq) were introduced into a 100-ml flask and dissolved in 200 ml of MeTHF (8 1 mol). The contents of the flask were stirred for 1 hour at room temperature. Then 11.663 g of Compound 'B' (77.4 wt-%, 29.53 mmol, 1.2 Eq) was added, and the reaction mixture was analysed after a reaction time of 18 hours. Analysis by LC indicated that Intermediate (2) had been obtained in a yield of 98.3%.
The reaction mixture was then extracted and washed first with two 180-ml portions of H20 (15 1/mol), and then with two 180-ml portions of an NaHC03 solution (15 1/mol). The organic layer was dried with 2.4 g of Na2S04 and filtered, after which the volume of the filtrate obtained was determined. 60 ml of MeTHF was added to make up the volume to 200 ml (81/M). Analysis by LC indicated that Intermediate (2) had been obtained in a yield of 93.7%.
Example 5
Compound 'A'
Figure imgf000009_0001
Experiment A
To 13.722 g of Intermediate (2) (16.4 wt-%, 1 Eq, 2.88 mmol) dissolved in MeTHF (8 1/mol) in a 100-ml flask without a nitrogen atmosphere(this solution contained 2.17 wt-% of water), 251 μΐ of water was added to bring the water content up to 4 wt-%. After the addition of 1.9 ml of MeS03H (1 Eq, 28.8 mmol), the reaction mixture was placed on an oil bath heated to 50°C. A sample was taken and analysed after a reaction time of 5 hours. After a reaction time of 22 hours, the reaction mixture was brought to room temperature, and sampled again for analysis. The whole reaction mixture weighed 15.022 g.
Analysis by LC
After 5 hours: 90.1% of Compound 'A'
After 22 hours: 75.4% of Compound 'A' Experiment B
119.6 g of Intermediate (2) (10.27 wt-%, 15.7 mmol, 1 Eq) was dissolved in MeTHF (8 1/mol) in a reaction vessel with a nitrogen atmosphere. The solution contained 2.21 wt-%) of water. 2.81 g of water were added to bring the water content up to 4 wt-%. After the addition of 10.31 ml of MeS03H (157 mmol, 10 Eq), the reaction mixture was heated to 50°C. After a reaction time of 5 hours, the reaction mixture was cooled to room temperature, and a sample of it was analysed. The whole reaction mixture weighed 1 19.6 g.
Analysis by LC

Claims

Claims
1. Method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2- {2-[methyl- (sulphamoyl)-amino]-ethoxy} -ethyl)-carbamoyl]-7H-indolo-[2, 1 -a]-[2]- benzazepine-10-carboxylic acid ('Compound A'), characterized in that it comprises the following steps:
a) 1 O-(fcrt-butoxycarbonyl)- 13-cyclohexyl-3-methoxy- 7H-indolo-[2, 1 -a]-[2]- benzazepine-6-carboxylic acid (Compound I) is reacted with te/ -butyl (methyl- {2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate
(Compound 'B') in the presence of a coupling agent in a suitable solvent, and
Figure imgf000010_0001
b) Compound (II) thus obtained is hydrolysed with an acid, so that Compound 'A' is obtained.
Figure imgf000010_0002
2. Method according to Claim 1 , where Steps a) and b) are carried out as a one-vessel synthesis. 3. Method according to Claim 1 or 2, where the coupling agent is chosen from
amongst carbodiimidazole (CDI), dicyclohexylcarbodiimide (DCC), 0-(7- azabenzotriazo le- 1 -yl)- 1 , 1 ,3 ,
3-tetramethyluronium hexafluorophosphate (HATU), bromotri-(pyrrolidino)-phosphonium hexafluorophosphate (PyBrOP), and a combination of 1-hydroxybenztriazole hydrate (HOBT.H20) and l-ethyl-3-(3- dimethylaminopropyl)-carbodiimide hydrochloride (EDCI).
4. Method according to any one of Claims 1-3, where the acid used in Step b) is
trifluoroacetic acid, methanesulphonic acid, hydrogen chloride, hydrogen bromide, ;?<2ra-toluenesulphonic acid, sulphuric acid or phosphoric acid.
5. Method according to any one of Claims 1-4, where the preparation is carried out in a nitrogen atmosphere.
6. Method according to Claim 5, where the solvent used in Step a) is
2-methyltetrahydrofuran.
7. Method according to Claim 6, where the organic acid used in Step b) is
methanesulphonic acid, the reaction temperature is 50°C, and the duration of the reaction is no longer than 5 hours.
8. tert-Butyl (methyl- {2-[2-(methylamino)-ethoxy]-ethyl} -sulphamoyl)-carbamate, and acid-addition salts thereof.
Figure imgf000011_0001
PCT/EP2011/060606 2010-06-24 2011-06-24 PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID WO2011161232A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
US13/805,607 US9127010B2 (en) 2010-06-24 2011-06-24 Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
CN201180030949.0A CN103097356B (en) 2010-06-24 2011-06-24 13-cyclohexyl-3-methoxyl group-6-[methyl-(2-{2-[methyl-(sulfamyl)-amino]-oxyethyl group }-ethyl)-formamyl]-7H-indoles also-[2,1-a]-preparation of [2]-benzo-aza *-10-carboxylic acid
CA2801517A CA2801517C (en) 2010-06-24 2011-06-24 Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7h-indolo-[2,1-.alpha.]-[2]-benzazepine-10-carboxylic acid
RU2013103004/04A RU2559886C2 (en) 2010-06-24 2011-06-24 OBTAINING 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{ 2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-α]-[2]-BENZAZEPIN-10-CARBOXYLIC ACID
EP11727184.1A EP2585438B1 (en) 2010-06-24 2011-06-24 PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
BR112012032889A BR112012032889A2 (en) 2010-06-24 2011-06-24 preparation of 13-cyclohexyl-3-methoxy-6- [methyl- (2- {2- [methyl- (sulfamoyl) -amino] -ethoxy} -ethyl) -carbamoyl] -7h-indol- [2, 1-a] - [2] benzazepine-10-carboxylic acid
MX2012015198A MX2012015198A (en) 2010-06-24 2011-06-24 PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(S ULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7<i>H</i>-INDOLO-[2, 1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID.
JP2013515907A JP5870098B2 (en) 2010-06-24 2011-06-24 13-Cyclohexyl-3-methoxy-6- [methyl- (2- {2- [methyl- (sulfamoyl) -amino] -ethoxy} -ethyl) -carbamoyl] -7H-indolo- [2,1-a]- [2] Production of benzazepine-10-carboxylic acid
AU2011268922A AU2011268922B2 (en) 2010-06-24 2011-06-24 Preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid
IL223427A IL223427A (en) 2010-06-24 2012-12-04 Methods of preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7h-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid and intermediates used therein
US14/810,783 US20150329482A1 (en) 2010-06-24 2015-07-28 Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10167221 2010-06-24
EP10167221.0 2010-06-24

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/806,607 A-371-Of-International US20130091758A1 (en) 2010-06-24 2011-06-22 Insect bait
US14/810,783 Division US20150329482A1 (en) 2010-06-24 2015-07-28 Preparation of 13-Cyclohexyl-3-Methoxy-6-[Methyl-(2-(2-[Methyl-(Sulphamoyl)-Amino]-Ethoxy}-Ethyl)-Carbamoyl]-7H-Indolo-{2,1-a]-[2]-Benzazepine-10-Carboxylic Acid

Publications (1)

Publication Number Publication Date
WO2011161232A1 true WO2011161232A1 (en) 2011-12-29

Family

ID=43216626

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/060606 WO2011161232A1 (en) 2010-06-24 2011-06-24 PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID

Country Status (11)

Country Link
US (2) US9127010B2 (en)
EP (1) EP2585438B1 (en)
JP (1) JP5870098B2 (en)
CN (1) CN103097356B (en)
AU (1) AU2011268922B2 (en)
BR (1) BR112012032889A2 (en)
CA (1) CA2801517C (en)
IL (1) IL223427A (en)
MX (1) MX2012015198A (en)
RU (1) RU2559886C2 (en)
WO (1) WO2011161232A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI454476B (en) 2008-07-08 2014-10-01 Tibotec Pharm Ltd Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003658A1 (en) 2008-07-08 2010-01-14 Tibotec Pharmaceuticals Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
SK286662B6 (en) 1996-04-23 2009-03-05 Vertex Pharmaceuticals Incorporated Urea derivatives, pharmaceutical compositions containing them, and their use as inhibitors of IMPDH enzyme activity
ES2201452T3 (en) 1997-03-14 2004-03-16 Vertex Pharmaceuticals Incorporated INHIBITORS OF THE IMPDH ENZYME.
EP1964561A1 (en) 1999-03-19 2008-09-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
JP4778665B2 (en) 2000-08-30 2011-09-21 パナソニック株式会社 Method for manufacturing plasma display device
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
KR20080040032A (en) 2005-09-02 2008-05-07 티보텍 파마슈티칼즈 리미티드 Benzodiazepines as hcv inhibitors
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
GB0522881D0 (en) 2005-11-10 2005-12-21 Angeletti P Ist Richerche Bio Therapeutic compounds
WO2007092000A1 (en) 2006-02-06 2007-08-16 Bristol-Myers Squibb Company Inhibitors of hcv replication
US7521443B2 (en) 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521442B2 (en) * 2006-05-25 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
EP2121707B1 (en) 2006-12-20 2012-12-05 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Antiviral indoles
AU2008277440A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis C infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010003658A1 (en) 2008-07-08 2010-01-14 Tibotec Pharmaceuticals Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Also Published As

Publication number Publication date
US20130102777A1 (en) 2013-04-25
US9127010B2 (en) 2015-09-08
RU2013103004A (en) 2014-07-27
RU2559886C2 (en) 2015-08-20
CN103097356B (en) 2016-01-13
IL223427A (en) 2015-04-30
AU2011268922A1 (en) 2013-01-10
JP5870098B2 (en) 2016-02-24
EP2585438A1 (en) 2013-05-01
CA2801517C (en) 2017-12-12
US20150329482A1 (en) 2015-11-19
CN103097356A (en) 2013-05-08
MX2012015198A (en) 2013-02-11
EP2585438B1 (en) 2014-08-20
CA2801517A1 (en) 2011-12-29
AU2011268922B2 (en) 2014-06-12
BR112012032889A2 (en) 2015-09-15
JP2013530976A (en) 2013-08-01

Similar Documents

Publication Publication Date Title
JP7063409B1 (en) How to remove the Fmоc group
CN107001294A (en) A kind of method for preparing Gadobutrol
WO2011161232A1 (en) PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2-{2-[METHYL-(SULPHAMOYL)-AMINO]-ETHOXY}-ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]-[2]-BENZAZEPINE-10-CARBOXYLIC ACID
JP2011513286A (en) Method for preparing combretastatin
CN109641901B (en) Abamebactam free acid
ES2656820T3 (en) Process for preparing biphenylimidazole compounds
AU766552B2 (en) A process for the preparation of 3-amino bile acid derivatives
JP6787331B2 (en) Method for producing acid halide solution, mixed solution, and method for producing monoester compound
US10501403B2 (en) Method for preparation of (S)-N1-(2-aminoethyl)-3-(4-alkoxyphenyl)propane-1,2-diamine trihydrochloride
KR100663167B1 (en) Process for preparing itopride hydrochloride
JP2009518380A (en) Preparation of 2-chloroethoxy-acetic acid-N, N-dimethylamide
JP7380555B2 (en) Manufacturing method of polymerizable compound
TW200804269A (en) Chemical process
AU2014343268B2 (en) Intermediates and methods for synthesizing calicheamicin derivatives
US20120302759A1 (en) Combretastatin derivative preparation method
CA2826086A1 (en) Process for preparation of caspofungin acetate and intermediates
CN110418797B (en) Method for preparing ketolide compound
KR100450607B1 (en) Process for preparing Galamin
WO2013140331A1 (en) New 1, 2, 4-oxadiazol derivatives, process for their preparation and use thereof as intermediates in the preparation of indolic alkaloids
EP2489655A1 (en) Process for preparation of diethylenetriaminepentaacetic acid derivatives, and diethylenetriaminepentaacetic acid derivatives
CN108840832A (en) A kind of preparation method of Gadobutrol intermediate
WO2013186248A1 (en) A method for the preparation of 3-amino-n-cyclopropyl-2-hydroxyl-hexanamide
WO2002008184A1 (en) Process for preparing distamycin derivatives
JPH0794414B2 (en) Optically active N-carboalkylated amino alcohol

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180030949.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11727184

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2801517

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 223427

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2013515907

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13805607

Country of ref document: US

Ref document number: MX/A/2012/015198

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2011268922

Country of ref document: AU

Date of ref document: 20110624

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011727184

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2013103004

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112012032889

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112012032889

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20121221